Dr Agarwal’s Health Care IPO, which was open from January 29 to 31, saw tepid investor interest, with retail and NII segments under-subscribed. Despite a strong foothold in the eye care sector, analysts expect a dull listing due to high valuations and ongoing market volatility. The IPO’s pricing is steep, but long-term growth potential remains.
Dr Agarwal’s Health Care Ltd, a prominent player in the Indian organized eye care sector, is set to list its shares on the stock exchanges on February 4, 2025. The company, known for its 25% market share in the country’s eye care industry, opened its initial public offering (IPO) from January 29 to 31. The issue raised ₹875.5 crore from anchor investors, but retail and non-institutional investors (NII) showed lukewarm interest, resulting in below 1x subscription for these segments.
The price band for the IPO was set between ₹382 and ₹402 per share, and despite a subscription of 1.55 times overall, the investor response has been cautious, largely reflecting ongoing market volatility. Analysts predict a tepid debut for Dr Agarwal’s Health Care, citing concerns about the company’s steep valuation and the broader market sentiment. With an estimated price-to-earnings ratio of 134 times its FY24 earnings, the pricing of the IPO has been a point of contention.
Prashanth Tapse, Senior VP Research at Mehta Equities Ltd, shared his expectations for the stock’s listing, suggesting a flat to slightly negative opening. He stated, “While Dr Agarwal’s Health Care dominates the eye care industry in India, the weak market sentiment has led to a subdued response. Investors should consider holding the stock for the long term and should wait for price stability post-listing.”
Sagar Shetty, Research Analyst at StoxBox, agreed with this cautious outlook, advising investors to refrain from entering the stock immediately. “Due to concerns around valuation and market trends, we recommend staying on the sidelines until the company’s financial performance becomes clearer in the coming quarters.”
Despite these concerns, analysts like Narendra Solanki from Anand Rathi Shares and Stock Brokers believe that Dr Agarwal’s Health Care has strong growth potential. Solanki noted, “While the IPO pricing is steep, the company’s position in the eye care sector warrants a long-term investment perspective.”
The proceeds from the fresh issue will be utilized for debt repayment, general corporate purposes, and potential acquisitions, as the company looks to expand its operations further.
As the stock prepares for its listing on February 4, investors are advised to remain cautious and monitor the market’s response carefully.
